[
  {
    "vignette_index": 507,
    "input": "Substance-Induced Psychotic Disorder END",
    "output": "THINKING: Use systematic clinical reasoning to develop my treatment approach:  STEP 1 - DIAGNOSIS CONFIRMATION & SEVERITY ASSESSMENT: Let me first confirm the diagnosis and assess severity/urgency. - Primary diagnosis confidence: High, given the recent onset of visual and auditory hallucinations related to inhalant use, with symptoms consistent with substance-induced psychosis. - Severity classification: Moderate, as the patient reports distress and disruption but no mention of suicidal ideation, self-harm, or danger to others at this time. - Urgency level: Urgent care needed, since psychotic symptoms pose safety concerns and need prompt intervention. - Differential considerations still requiring monitoring: Underlying primary psychotic disorder (e.g., schizophrenia), other substance toxidromes, or medical causes like neurological issues.  STEP 2 - EVIDENCE-BASED TREATMENT SELECTION: Now I'll select treatments based on current clinical guidelines. - First-line treatment per guidelines: Abstinence from inhalants and supportive management; consider antipsychotic medication if symptoms persist or worsen. - Supporting evidence: Substance-induced psychosis often resolves with detoxification and abstinence; symptomatic treatment with antipsychotics is indicated for significant psychosis. - Patient-specific considerations: Since inhalant use appears recent and fluctuating, emphasizing detoxification is priority. - Contraindications or cautions: Avoid dependence on long-term antipsychotics unless symptoms persist beyond substance clearance; monitor for side effects.  STEP 3 - PHARMACOLOGICAL INTERVENTIONS: If medications are appropriate, I'll select based on efficacy and safety. - Primary medication choice: Atypical antipsychotic such as risperidone 1-2 mg daily, titrated as needed. - Rationale for selection: Risperidone has a favorable side effect profile and is effective in managing acute psychosis. - Expected timeline for improvement: Symptom reduction within 1-2 weeks. - Key side effects to monitor: Extrapyramidal symptoms, metabolic syndrome, sedation\u2014regular follow-up and labs recommended. - Alternative medications if first-line fails: Olanzapine, aripiprazole, or quetiapine.  STEP 4 - NON-PHARMACOLOGICAL INTERVENTIONS: I'll include lifestyle and behavioral interventions that enhance outcomes. - Primary non-drug interventions: Psychoeducation about inhalant effects and detoxification. - Patient education priorities: Risks of inhalant use, importance of abstinence, and recognizing early warning signs. - Lifestyle modifications: Supportive environment, stress management, adequate sleep, avoiding triggers. - Behavioral interventions: Motivational interviewing, cognitive-behavioral therapy (CBT) for substance use and psychosis symptoms.  STEP 5 - MONITORING & FOLLOW-UP STRATEGY: I'll establish appropriate monitoring and follow-up care. - Follow-up timeline: Reassess in 1-2 weeks for symptom progression and medication tolerance. - Monitoring parameters: Psychotic symptoms severity, medication side effects, inhalant abstinence. - Red flag symptoms: Increased agitation, suicidal ideation, worsening hallucinations, or violence\u2014urgent care needed. - Treatment response assessment: Symptom charts, patient self-reporting, collateral input if possible.  STEP 6 - PATIENT COMMUNICATION STRATEGY: Given the patient's behavioral type (baseline), how should I communicate this plan? - Communication approach: Clear, non-confrontational, emphasizing the temporary nature of symptoms and the importance of abstinence. - Addressing patient concerns: Reassure about symptom resolution with treatment, address fears about impairment. - Adherence strategies: Simplify instructions, involve patient in planning, motivate engagement. - Family involvement: With patient consent, involve family or supportive persons for monitoring and encouragement.  STEP 7 - COORDINATION & REFERRALS: What additional care coordination is needed? - Specialist referrals needed: Psychiatry for ongoing assessment and medication management. - Other healthcare team members: Social work for substance use support, mental health counselors. - Community resources: Support groups for inhalant users, crisis intervention services. - Insurance/cost considerations: Discuss coverage for medication, therapy sessions, and follow-up visits.\nANSWER: Based on the diagnosis of Volatile inhalant-induced psychotic disorder, I recommend a comprehensive treatment approach that combines prompt detoxification and abstinence with symptomatic management and psychosocial support. The initial focus is on ensuring inhalant cessation, initiating an atypical antipsychotic such as risperidone 1-2 mg daily to control psychotic symptoms, and providing psychoeducation. Supportive and behavioral interventions including motivational interviewing and cognitive-behavioral therapy are essential for addressing substance use behaviors and preventing relapse. Close outpatient follow-up within 1-2 weeks is critical to monitor symptom progression, medication tolerability, and inhalant abstinence. Continuous assessment of safety, symptom improvement, and adherence will guide long-term management, aiming for full resolution of psychosis and sustained abstinence. Efforts should include collaboration with mental health specialists, social services, and community resources to support recovery and prevent future episodes.  IMPLEMENTATION GUIDANCE: - Immediate actions (today): Arrange psychiatric consultation, initiate psychoeducation, and identify support persons. - Short-term goals (1-4 weeks): Achieve inhalant abstinence, reduce hallucinations with medication, and evaluate safety. - Long-term objectives (3-6 months): Maintain abstinence, stabilize mental health, and develop relapse prevention strategies. - Patient handout summary: Emphasize the importance of abstinence, medication adherence, and follow-up visits to ensure recovery.",
    "gold_diagnosis": "Volatile inhalant-induced psychotic disorder"
  }
]